Testing two medicines together for lymphoma that hasn't responded to past treatment

Plain-English translation of NCT06484920 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated August 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether combining with all-trans retinoic acid () can help treat lymphoma that has returned or didn't respond to previous treatments. is a medication that helps your immune system recognize and fight cancer cells. The researchers believe that adding to may make the treatment even more effective.

Many patients with lymphoma eventually have their cancer come back or find that standard treatments stop working. This trial explores whether using the medication in a new combination might offer hope to people who have limited options left.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with Hodgkin lymphoma or B-cell non-Hodgkin lymphoma that has either come back after treatment or didn't respond to past treatment
you have a doctor's assessment that you can handle this treatment (good enough physical condition)
you have a life expectancy of at least 12 weeks
your blood counts and organ function (kidney, liver) are adequate based on recent lab work
if you can become pregnant, you have a negative pregnancy test before starting

You likely don't qualify if…

you have active or uncontrolled other cancers besides your lymphoma
you have severe organ dysfunction that would make it unsafe to receive these medicines
you are pregnant or breastfeeding
you have a known severe allergy to either of the study medications
you cannot commit to the study visits and follow-up schedule

What participation looks like

You will receive the medication by IV infusion every 3 weeks. Around your first four infusions, you will also take tablets by mouth for 3 days (the day before, the day of, and the day after each infusion). You'll have regular blood tests and doctor visits to monitor how you're responding and to check for any side effects. The study involves 24 patients and is taking place at a single medical center.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(2 sites)

United States

Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana